Reference no: EM132844861

The efficacy of a new addiction medication was evaluated in a randomized, placebo-controlled, doubleblind study. The medication in question, Antaquil, is intended to moderate the symptoms of alcohol withdrawal and craving with minimum side effects. Over the course of three weeks, a sample of 36 individuals who were recovering from alcohol addiction were randomly assigned to two groups: one administered the medication and one administered a placebo. At the end of the designated period, participants were administered the Obsessive Compulsive Drinking Scale (OCDS), an instrument that provides a global measure of thoughts about alcohol during nondrinking periods. Scores can range from 0 to 40 with higher scores signaling higher levels of rumination about alcohol. Prior to participation participants were all informed of the nature of Antaquil and were told they could leave the study at any time. Outcome data on the OCDS are shown below

Treatment Gp Placebo Gp

40 37
35 35
27 34
18 24
30 29
28 14
11 23
23 25
30 32
13 37
16 30
17 30
26 29
22 22
19 23
17 31
29 28
10 20

What can I say to summarize the data set presented?